Last updated: March 21, 2026
What is the drug associated with NDC 50742-0176?
NDC 50742-0176 corresponds to Tucatinib (brand name: Tukysa). Tucatinib is an oral kinase inhibitor used in the treatment of HER2-positive breast cancer.
Market Overview
Tucatinib entered the oncology market post-FDA approval in April 2020, targeting advanced or metastatic HER2-positive breast cancer resistant to other treatments. It gained accelerated approval based on trial data showing efficacy in patients with brain metastases.
Key Market Drivers
- Growing incidence of HER2-positive breast cancer
- Increasing approval and acceptance of targeted therapies
- Rising prevalence of brain metastases within HER2-positive subpopulation
- Limited competition in specific indications
Market Size (2022-2027)
- Global HER2-positive breast cancer market was valued at approximately USD 5.3 billion in 2022.
- Tucatinib's incremental contribution expected to grow from USD 150 million in 2022 to USD 600 million by 2027.
- Market share projections suggest tucatinib capturing 5-10% of the HER2 therapy market over five years, as competition remains limited but competitive pressures from other HER2-targeted agents increase.
Key Competitors
- Trastuzumab deruxtecan (Enhertu)
- Pertuzumab (Perjeta)
- Trastuzumab (Herceptin)
- Neratinib (Nerlynx)
- Neratinib and tucatinib are most directly comparable for HER2-positive metastatic breast cancer with brain metastases.
Pricing and Reimbursement Landscape
Current List Price
- Estimated list price for tucatinib (Tukysa): USD 10,000 – USD 12,000 per month per patient.
- Price varies based on packaging, payer negotiations, and regional markets.
Reimbursement Status
- FDA approved for HER2-positive breast cancer with prior therapies.
- Covered by major payers in the US, including Medicare and Medicaid, based on indications.
- International pricing varies, with some markets implementing cost-effectiveness assessments.
Cost-Effectiveness and Value
- Cost-effectiveness analyses in the US suggest a cost per quality-adjusted life year (QALY) exceeding USD 150,000, but willingness-to-pay thresholds are region-dependent.
- Breakeven or value-based pricing could be driven down by biosimilar competition and payer negotiations.
Price Projections (2023-2027)
| Year |
Estimated Average Monthly Price |
Key Factors |
| 2023 |
USD 11,500 |
Current market dynamics, stable demand, no biosimilar entry |
| 2024 |
USD 11,250 |
Slight price pressure from payer negotiations |
| 2025 |
USD 10,900 |
Increasing competition, potential biosimilar emergence in niche indications |
| 2026 |
USD 10,500 |
Market saturation, stricter reimbursement policies |
| 2027 |
USD 10,200 |
Greater biosimilar presence, discounting trends accelerate |
Pricing will be influenced by:
- Biosimilar and generic product development
- Payer market access strategies
- Emerging clinical data impacting label expansion
- Regional formulary negotiations
Regulatory and Patent Landscape
Patent Status
- Original patents expired or expected to expire by 2027.
- Patent extensions or formulations may extend exclusivity in specific markets.
Regulatory Pathways
- Orphan drug designation reduced development costs.
- Potential for additional approval in combination therapies.
Key Challenges
- Biosimilar competition could reduce prices by 20-30% upon launch.
- Pricing caps and cost-effectiveness models impose pressure.
- Increasing competition could slow sales growth beyond 2027.
Opportunities
- Label expansions for earlier lines of therapy or additional indications.
- Combination therapies presenting higher-value propositions.
- International markets with limited competition and higher acceptance of new oncology drugs.
Key Takeaways
- Tucatinib is a specialized agent in HER2-positive breast cancer, with increasing market penetration.
- Its price remains high, but competition and biosimilars could drive reductions from 2025 onward.
- The global market growth project USD 600 million by 2027, driven by prevalence and clinical demand.
- Reimbursement depends on regional policies; US reimbursement stabilizes, while other markets vary.
- Price reductions of 15-20% are likely within five years due to biosimilar entry and market saturation.
FAQs
1. Will tucatinib’s price decrease significantly with biosimilar competition?
Yes. Biosimilars typically launch 8-12 years post-patent expiry, reducing prices by 20-30%.
2. Are there emerging indications that could expand tucatinib’s market?
Yes. Clinical trials exploring early-line therapy, combination strategies, and other cancers could extend its market.
3. How does tucatinib compare in price to similar HER2-targeted therapies?
It is priced higher than some agents like neratinib but lower than combination regimens involving monoclonal antibodies.
4. What factors could accelerate or delay the entry of biosimilars?
Regulatory delays, patent litigation, and market size influence biosimilar timing.
5. What are the key regulatory hurdles for expanding tucatinib’s use?
Gathering robust clinical evidence for new indications and navigating region-specific approval pathways.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2020). Tucatinib approval letter.
[3] PricewaterhouseCoopers. (2022). Oncology Drug Pricing and Market Dynamics.
[4] Oncology Data Monitor. (2023). HER2-positive Breast Cancer Market Trends.
[5] NHS Digital. (2023). International comparison of oncology reimbursement policies.
